Skip to main content
OTCMKTS:SUWN

Sunwin Stevia International Competitors

$0.05
0.00 (0.00 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.05
$0.05
50-Day Range
$0.05
$0.07
52-Week Range
$0.04
$0.15
Volume10,500 shs
Average Volume65,617 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta1.18

Competitors

Sunwin Stevia International (OTCMKTS:SUWN) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying SUWN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Sunwin Stevia International, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Sunwin Stevia International (OTCMKTS:SUWN) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares Sunwin Stevia International and Acusphere's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sunwin Stevia International$26.09 millionN/A$-1,380,000.00N/AN/A
AcusphereN/AN/AN/AN/AN/A

Acusphere has lower revenue, but higher earnings than Sunwin Stevia International.

Risk and Volatility

Sunwin Stevia International has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Acusphere has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Sunwin Stevia International and Acusphere, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sunwin Stevia International0000N/A
Acusphere0000N/A

Profitability

This table compares Sunwin Stevia International and Acusphere's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sunwin Stevia International-9.56%-24.05%-7.89%
AcusphereN/AN/AN/A

Summary

Acusphere beats Sunwin Stevia International on 3 of the 5 factors compared between the two stocks.

Sunwin Stevia International (OTCMKTS:SUWN) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares Sunwin Stevia International and Affymax's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sunwin Stevia International$26.09 millionN/A$-1,380,000.00N/AN/A
AffymaxN/AN/AN/AN/AN/A

Affymax has lower revenue, but higher earnings than Sunwin Stevia International.

Risk and Volatility

Sunwin Stevia International has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Sunwin Stevia International and Affymax, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sunwin Stevia International0000N/A
Affymax0000N/A

Profitability

This table compares Sunwin Stevia International and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sunwin Stevia International-9.56%-24.05%-7.89%
AffymaxN/AN/AN/A

Summary

Affymax beats Sunwin Stevia International on 4 of the 5 factors compared between the two stocks.

Sunwin Stevia International (OTCMKTS:SUWN) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares Sunwin Stevia International and ARYx Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sunwin Stevia International$26.09 millionN/A$-1,380,000.00N/AN/A
ARYx TherapeuticsN/AN/AN/AN/AN/A

ARYx Therapeutics has lower revenue, but higher earnings than Sunwin Stevia International.

Risk and Volatility

Sunwin Stevia International has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Sunwin Stevia International and ARYx Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sunwin Stevia International0000N/A
ARYx Therapeutics0000N/A

Profitability

This table compares Sunwin Stevia International and ARYx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sunwin Stevia International-9.56%-24.05%-7.89%
ARYx TherapeuticsN/AN/AN/A

Summary

ARYx Therapeutics beats Sunwin Stevia International on 3 of the 5 factors compared between the two stocks.

Sunwin Stevia International (OTCMKTS:SUWN) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Sunwin Stevia International and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sunwin Stevia International-9.56%-24.05%-7.89%
AtheroNovaN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Sunwin Stevia International and AtheroNova, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sunwin Stevia International0000N/A
AtheroNova0000N/A

Valuation and Earnings

This table compares Sunwin Stevia International and AtheroNova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sunwin Stevia International$26.09 millionN/A$-1,380,000.00N/AN/A
AtheroNovaN/AN/AN/AN/AN/A

AtheroNova has lower revenue, but higher earnings than Sunwin Stevia International.

Risk and Volatility

Sunwin Stevia International has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500.

Summary

AtheroNova beats Sunwin Stevia International on 3 of the 5 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Sunwin Stevia International (OTCMKTS:SUWN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Profitability

This table compares China Botanic Pharmaceutical and Sunwin Stevia International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Botanic PharmaceuticalN/AN/AN/A
Sunwin Stevia International-9.56%-24.05%-7.89%

Analyst Ratings

This is a breakdown of recent ratings and price targets for China Botanic Pharmaceutical and Sunwin Stevia International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Botanic Pharmaceutical0000N/A
Sunwin Stevia International0000N/A

Valuation & Earnings

This table compares China Botanic Pharmaceutical and Sunwin Stevia International's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Botanic PharmaceuticalN/AN/AN/AN/AN/A
Sunwin Stevia International$26.09 millionN/A$-1,380,000.00N/AN/A

China Botanic Pharmaceutical has higher earnings, but lower revenue than Sunwin Stevia International.

Risk & Volatility

China Botanic Pharmaceutical has a beta of 17.09, indicating that its stock price is 1,609% more volatile than the S&P 500. Comparatively, Sunwin Stevia International has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Summary

China Botanic Pharmaceutical beats Sunwin Stevia International on 4 of the 5 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and Sunwin Stevia International (OTCMKTS:SUWN) are both consumer staples companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Profitability

This table compares China Dongsheng International and Sunwin Stevia International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Dongsheng InternationalN/AN/AN/A
Sunwin Stevia International-9.56%-24.05%-7.89%

Analyst Ratings

This is a breakdown of recent ratings and price targets for China Dongsheng International and Sunwin Stevia International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Dongsheng International0000N/A
Sunwin Stevia International0000N/A

Valuation & Earnings

This table compares China Dongsheng International and Sunwin Stevia International's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Dongsheng InternationalN/AN/AN/AN/AN/A
Sunwin Stevia International$26.09 millionN/A$-1,380,000.00N/AN/A

China Dongsheng International has higher earnings, but lower revenue than Sunwin Stevia International.

Risk & Volatility

China Dongsheng International has a beta of 13.38, indicating that its stock price is 1,238% more volatile than the S&P 500. Comparatively, Sunwin Stevia International has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Summary

China Dongsheng International beats Sunwin Stevia International on 4 of the 5 factors compared between the two stocks.


Sunwin Stevia International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.08flat$0.00N/A0.00Gap Down
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00Gap Down
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.05flat$0.00N/A0.00Gap Down
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20Upcoming Earnings
DDXSQ
Diadexus
0.0$0.00flat$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$32.89flat$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.90flat$0.00$263.61 million0.00Gap Up
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Gap Down
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Down
PARD
Poniard Pharmaceuticals
0.5$0.09flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00High Trading Volume
Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.